4-AcO-DET (4-acetoxy-N,N-diethyltryptamine), also known as ethacetin or 4-acetoxy-DET, is a synthetic psychedelic tryptamine that functions as a prodrug for its 4-hydroxy analog, 4-HO-DET. It belongs to the acetylated psilocybin analog family — a group of compounds that are structurally related to psilocybin and metabolize to pharmacologically active 4-hydroxy tryptamines upon ingestion. First described in the scientific literature by Albert Hofmann and Franz Troxler in 1963, 4-AcO-DET occupies a relatively obscure position in the tryptamine family despite sharing a mechanism of action with psilocybin and the better-known 4-AcO-DMT.
The experience profile of 4-AcO-DET is broadly psychedelic in character — users report visual geometry, emotional amplification, introspective depth, and alterations in the perception of time — but with a character described by many as somewhat warmer and more visual than 4-AcO-DMT at equivalent doses. Community experience reports frequently emphasize aesthetic beauty: enhanced appreciation of art, music, and natural environments features prominently. The compound is generally considered to sit in the middle of the tryptamine potency range, with active doses typically falling between 10–25 mg orally.
As with other 4-AcO compounds, 4-AcO-DET produces effects comparable to psilocybin mushrooms in character, with the acetylation serving primarily to improve oral bioavailability relative to the free 4-HO compound. The duration is typically 4–6 hours — somewhat shorter than LSD or 2C-B, making it a practical choice for experienced users seeking a full but temporally bounded psychedelic experience.
Safety at a Glance
High Risk- Obtain and Verify Your Substance
- Threshold: 5–10 mg | Low: 10–15 mg | Common: 15–25 mg | Strong: 25–40 mg
- Toxicity: Acute Toxicity 4-AcO-DET has no established formal toxicity data in humans. Based on its structural relationship to p...
- Overdose risk: Fatal overdose from 4-AcO-DET alone, at doses within the typical recreational range, is extremely...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4 hrs – 7 hrsHow It Feels
The first sign arrives as a gentle fizzing sensation behind the eyes, spreading outward through the temples and down into the jaw within twenty to thirty minutes of ingestion. A warmth settles into the chest — not the sharp heat of stimulation, but something more like the slow radiance of afternoon sunlight through curtains. The stomach may turn slightly, a brief knot of nausea that loosens as the body adjusts. Colors begin to shift in subtle ways: reds deepen toward burgundy, greens acquire a luminous, almost backlit quality, and there is a strange new depth to shadows, as though darkness itself has become a color.
As the come-up builds over the next thirty to sixty minutes, the visual field opens dramatically. Surfaces ripple with intricate patterning — not the rigid geometric lattices of lysergamides, but something more organic and flowing, like watching oil spread across water or light refracted through antique glass. Closed-eye visuals bloom in rich, saturated palettes: spiraling tunnels of amber and teal, crystalline structures that fold and unfold with each breath. There is a dreamlike quality to thought — ideas arrive not in linear sequences but in clusters, each one trailing threads of association and memory. Music becomes deeply absorbing, each note seeming to carry emotional information that bypasses language entirely.
At the peak, which settles in around ninety minutes and persists for two to three hours, 4-AcO-DET reveals its distinctive character: a headspace that is simultaneously contemplative and oddly lighthearted. Unlike the heavy introspective gravity of psilocin or the analytical clarity of lysergamides, this compound encourages a kind of playful philosophical wandering. Thoughts feel important but not urgent, profound but not burdensome. The ego softens without dissolving entirely, leaving a comfortable sense of perspective. The body feels pleasantly heavy and warm, as though wrapped in something soft.
The descent is gradual and unhurried, unfolding over two to three hours. The vivid patterning slowly recedes to a gentle shimmer, and the dreamlike ideation gives way to a calm lucidity. Physical tiredness sets in gently, accompanied by a lingering warmth in the limbs and a sense of having traveled somewhere meaningful and returned safely. The afterglow often carries a quiet satisfaction, a renewed appreciation for simple things — the texture of a blanket, the complexity of a friend's face, the way evening light falls across a room.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(21)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Runny nose— Excessive nasal discharge commonly occurring during opioid withdrawal or from nasal irritation cause...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Stomach bloating— Stomach bloating is the uncomfortable distension of the abdomen resulting from gas accumulation, flu...
- Stomach cramp— Stomach cramps are sharp, intermittent pains in the abdominal region that can occur when psychoactiv...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Watery eyes— Excessive tear production causing overflow tearing and blurred vision, commonly occurring during opi...
Cognitive & Perceptual Effects
Visual(17)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(17)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Autonomous voice communication— Autonomous voice communication is the experience of hearing and engaging in conversation with one or...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Enhancement and suppression cycles— Enhancement and suppression cycles is a distinctive cognitive effect in which the mind alternates be...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(1)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Perception of predeterminism— Perception of predeterminism is the powerful subjective experience of feeling — not merely thinking,...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
4-AcO-DET is hypothesized to function primarily as a prodrug. Following oral administration, plasma esterases rapidly cleave the acetyl group to yield 4-HO-DET (4-hydroxy-N,N-diethyltryptamine), the active free-phenol compound. 4-HO-DET then acts as a partial agonist at serotonin 5-HT2A receptors, the primary molecular target responsible for classical psychedelic effects across the tryptamine and phenethylamine families.
Whether 4-AcO-DET itself has any direct pharmacological activity prior to hydrolysis remains uncertain — some researchers have proposed that the intact acetylated molecule may cross the blood-brain barrier more efficiently and be hydrolyzed intracellularly, but definitive human pharmacokinetic data is lacking.
Serotonin Receptor Pharmacology
At 5-HT2A receptors, 4-HO-DET acts as a biased partial agonist, activating downstream signaling cascades including phospholipase C (Gq pathway) and β-arrestin recruitment. This leads to increased glutamate release in the prefrontal cortex and disruption of the brain's hierarchical sensory processing (predictive coding), producing the characteristic perceptual and cognitive alterations. Additional activity at 5-HT2C, 5-HT1A, and potentially other serotonin receptor subtypes contributes to the full pharmacological profile.
Pharmacokinetics
Oral bioavailability is substantially enhanced by the acetyl group relative to 4-HO-DET. Onset after oral dosing is typically 30–60 minutes, with peak effects at 2–3 hours. Total duration is approximately 4–6 hours. The compound undergoes hepatic metabolism following hydrolysis. No formal human pharmacokinetic studies have been conducted.
Tolerance and Cross-Tolerance
Functional tolerance develops rapidly with repeated use, substantially diminishing effects within 24–48 hours. Complete cross-tolerance exists with psilocybin, psilocin, DMT, and other 5-HT2A agonist psychedelics. Tolerance reverses over approximately 5–7 days.
Detection Methods
Urine Detection
4-AcO-DET is not targeted by standard immunoassay-based urine drug screens. As a prodrug, 4-AcO-DET is rapidly hydrolyzed in vivo to its corresponding 4-HO (psilocin-type) metabolite, and it is primarily this metabolite that would be detected in biological specimens. Specialized LC-MS/MS methods can detect 4-substituted tryptamine metabolites in urine for approximately 24 to 48 hours after ingestion. The detection window is relatively short compared to many other drug classes due to the rapid hepatic metabolism and renal clearance of tryptamine compounds. Psilocin (4-HO-DMT) is the most commonly targeted analyte in specialized tryptamine panels, and structural analogs may or may not be captured depending on the specific method.
Blood and Serum Detection
Blood detection windows for 4-AcO-DET are short, typically 4 to 12 hours after oral ingestion. Peak plasma concentrations of the active metabolite occur within 1 to 2 hours. The rapid first-pass metabolism means that parent compound concentrations in blood are often negligible for 4-AcO prodrugs, while 4-HO compounds themselves are measured directly. LC-MS/MS is required for reliable serum detection at the low concentrations involved.
Standard Drug Panel Inclusion
4-AcO-DET is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. Tryptamines do not cross-react with immunoassay targets for any of the standard panel analytes (amphetamines, cannabinoids, cocaine metabolites, opiates, PCP, benzodiazepines, or barbiturates). Detection requires a specific request for tryptamine or novel psychoactive substance testing at a reference laboratory. Some extended forensic panels include psilocin, which may capture certain 4-substituted tryptamines, but this coverage is not guaranteed for all structural variants.
Confirmatory Methods
Confirmatory identification of 4-AcO-DET relies on LC-MS/MS with reference standards specific to the compound or its expected metabolites. GC-MS can also be used following appropriate derivatization. Immunoassay-based methods for psilocybin and psilocin exist but show variable cross-reactivity with structural analogs and are not considered reliable for novel 4-substituted tryptamines. Reference laboratories specializing in novel psychoactive substances offer the most comprehensive detection capabilities.
Reagent Testing (Harm Reduction)
The Ehrlich reagent is the primary harm reduction tool for 4-AcO-DET. A sample placed on the reagent should produce a purple to violet color change, confirming the presence of an indole ring system characteristic of tryptamines. This reaction is shared with LSD, psilocybin, DMT, and all indole-containing compounds, so it confirms the general class but not the specific identity. The Hofmann reagent provides a confirmatory blue to violet reaction for tryptamines. The Marquis reagent typically shows no reaction or a dark brown discoloration with 4-substituted tryptamines. A positive Ehrlich result significantly reduces the probability that the substance is a dangerous substitute such as an NBOMe compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins and Early Research
4-AcO-DET was first synthesized and described by Albert Hofmann and Franz Troxler in their landmark 1963 patent filed on behalf of Sandoz Laboratories — the same institution that brought LSD to the world. The patent, titled "Indole derivatives," described a series of 4-substituted tryptamine esters including 4-AcO-DMT, 4-AcO-DET, and related compounds. The work emerged from Hofmann's broader program of investigating psilocybin analogs following the isolation of psilocybin from Psilocybe mexicana in 1958.
The Sandoz Era
The Sandoz patent established the foundational chemistry of the 4-acetoxy tryptamine class but did not result in pharmaceutical development. Clinical investigation of these compounds remained minimal compared to LSD and psilocybin itself, which were the primary research focuses of the era. With the wave of psychedelic prohibition in the late 1960s and early 1970s, academic investigation ceased entirely.
Research Chemical Era
4-AcO-DET re-emerged as a research chemical in the early 2000s, popularized partly through Alexander Shulgin's encyclopedic documentation of tryptamine pharmacology and the growing online psychedelic community. Unlike psilocybin (Schedule I in the US), the legal status of 4-AcO compounds occupied a gray zone in many jurisdictions — the acetylated form was not explicitly scheduled, though enforcement interpretations have varied. This legal ambiguity contributed to its availability in the research chemical market.
Contemporary Context
4-AcO-DET remains one of the more obscure members of the 4-AcO tryptamine family. The broader renaissance of psychedelic research has not yet specifically examined 4-AcO-DET, with most clinical attention focused on psilocybin, LSD, and DMT. Community documentation of its effects continues to develop through harm reduction forums and experience reports.
Harm Reduction
Obtain and Verify Your Substance
4-AcO-DET circulates almost exclusively in the research chemical market. Obtain from reputable, established vendors and test before use. An Ehrlich reagent (turns purple/violet with indole-containing compounds) is a basic but essential first check. A more specific confirmation can be obtained using an Hofmann reagent.
Dose Carefully
- Threshold: 5–10 mg |Low: 10–15 mg |Common: 15–25 mg |Strong: 25–40 mg
- First-time users should start at 10–15 mg to assess sensitivity. Individual responses vary considerably.
- Weigh doses precisely with a milligram-accurate scale — eyeballing powder doses is never acceptable.
- Onset can be slow (up to 90 minutes on a full stomach); do not redose before the first dose has peaked.
Set and Setting
Community experience and clinical psychedelic research align: the quality of preparation, environment, and emotional state at the time of use are the primary determinants of experience outcome — not the compound itself.
- Choose a safe, comfortable, familiar space. Outdoors in nature is frequently cited as ideal for the aesthetic dimension of 4-AcO-DET.
- Resolve major stressors before the session; avoid use during acute emotional crises.
- A trusted, sober companion (trip sitter) dramatically reduces the risk of a difficult experience becoming genuinely distressing.
During the Experience
- Do not operate vehicles or machinery under any circumstances.
- If anxiety arises, change setting (go outside, change music), focus on breathing, and remind yourself that the state is time-limited.
- Benzodiazepines (diazepam 10 mg) reliably reduce tryptamine intensity without dangerous interactions and are the harm reduction standard for aborting a difficult experience.
Avoid Dangerous Combinations
- Lithium — Absolute contraindication; risk of seizures
- MAOIs — Potentiation, serotonin syndrome risk
- Tramadol — Seizure risk
- Cannabis — Profound, unpredictable intensity amplification
Toxicity & Safety
Acute Toxicity
4-AcO-DET has no established formal toxicity data in humans. Based on its structural relationship to psilocybin and psilocin — compounds with extensively documented low acute toxicity — 4-AcO-DET is presumed to have a broad safety margin at doses relevant to psychedelic use. No documented fatalities attributable to 4-AcO-DET pharmacology have been identified in the scientific or harm reduction literature.
Physiological Effects
As a serotonergic psychedelic, 4-AcO-DET produces mild sympathomimetic effects: pupil dilation, modest increases in heart rate and blood pressure, and in some users nausea during the onset phase. These effects are generally dose-dependent and well tolerated in healthy individuals without cardiovascular contraindications.
Psychological Risks
The primary risks are psychological rather than physiological:
- Anxiety and panic reactions — Dose-dependent; substantially increased risk at doses above 25 mg or in unfamiliar/unsupportive settings. Community reports describe the onset phase as the most vulnerable period.
- Challenging experiences — Like all serotonergic psychedelics, 4-AcO-DET can surface difficult psychological content. This is not inherently harmful but may require emotional processing afterward.
- HPPD — Hallucinogen Persisting Perception Disorder has been reported following use of tryptamine psychedelics generally; the frequency with 4-AcO-DET specifically is unknown but likely low.
- Psychiatric vulnerability — Individuals with personal or family history of psychosis, schizophrenia, or bipolar I disorder carry substantially elevated risk of adverse psychological outcomes.
Drug Interactions
- MAOIs — Potentiation is theoretically possible; combination carries risk of serotonin syndrome and unpredictably intensified effects. Avoid.
- Lithium — Contraindicated in combination with serotonergic psychedelics; risk of seizures.
- Cannabis — Community reports consistently describe cannabis as dramatically amplifying tryptamine intensity in an unpredictable manner; use with caution.
- SSRIs/SNRIs — May blunt effects via 5-HT2A downregulation; abrupt SSRI discontinuation to "feel" psychedelics is dangerous.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from 4-AcO-DET alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
Due to its relative obscurity, the possession and sale of 4-AcO-DET is unscheduled in most countries.
Germany: Because it is an ester of DET, 4-AcO-DET is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of January 24, 1974. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Japan: 4-AcO-DET is a controlled substance in Japan effective July 29th, 2015.
Switzerland: 4-AcO-DET is a controlled substance specifically named under Verzeichnis E.
Sweden: 4-AcO-DET was classified under the Act on the Prohibition of Certain Goods Dangerous to Health on November 1, 2005, making it illegal to sell or possess.
Turkey:** 4-AcO-DET is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: 4-AcO-DET is a Class A drug in the UK as it is an ester of the drug 4-HO-DET, which is a Class A drug as a result of the tryptamine catch-all clause.
United States: 4-AcO-DET is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
Responsible use
Research chemical
Hallucinogen
Tryptamine
4-HO-DET
4-AcO-DET (Wikipedia)
4-AcO-DET (Erowid Vault)
4-AcO-DET (Isomer Design)
Discussion
The Big & Dandy 4-AcO-DET Thread (Bluelight)
Experience Reports (1)
Tips (4)
Use a milligram scale to weigh 4-AcO-DET if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
Have a trip sitter present, ideally someone with psychedelic experience. They should remain calm and reassuring without being intrusive. A good sitter can make the difference between a challenging experience and a genuine crisis.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 4-AcO-DET and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Keep a benzodiazepine like alprazolam on hand as an emergency trip abort tool when using 4-AcO-DET. Even just knowing you have one available provides psychological reassurance. It will not fully end the trip but significantly reduces intensity.
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 4-AcO-DET - TripSit Factsheet
TripSit factsheet for 4-AcO-DET
tripsit - 4-AcO-DET - Wikipedia
Wikipedia article on 4-AcO-DET
wikipedia